## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.55 indicates fundamental undervaluation. Quality metrics strong (ROE 16%). Consistent execution (3/4 quarters beat estimates). Caution: declining volume (59% of avg), momentum weakening (-1.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($263.62)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bearish (Bullish: 0, Bearish: 3)

**1. Levi & Korsinsky Reminds Shareholders of an Investigation into The Cigna Group (CI) Regarding Potential Securities Fraud Allegations**
- Source: ACCESS Newswire | 20251222T140602 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE:CI) concerning potential federal securities law violations. This follows a significant drop in CI's stock price by 17% on October 30, 2025, after the company reported an increased Healthcare MCR for Q3 2025, which reduced future profitability expectations. Shareholders are encouraged to seek additional information regarding these allegations.

**2. Levi & Korsinsky Reminds Shareholders of an Investigation into The Cigna Group (CI) Regarding Potential Securities Fraud Allegations**
- Source: KXAN Austin | 20251222T130815 | Bearish | Relevance: 100%
- Levi & Korsinsky has initiated an investigation into The Cigna Group (NYSE:CI) concerning potential securities fraud. This follows a significant drop in CI's stock price by 17% on October 30, 2025, after the company reported third-quarter earnings showing a higher Healthcare Medical Care Ratio (MCR) of 84.8% compared to 82.8% in Q3 2024, impacting future profitability. The firm encourages affected investors to seek additional information regarding potential legal action.

**3. Levi & Korsinsky Reminds Shareholders of an Investigation into The Cigna Group (CI) Regarding Potential Securities Fraud Allegations**
- Source: FOX40 News | 20251222T073900 | Bearish | Relevance: 100%
- Levi & Korsinsky has initiated an investigation into The Cigna Group (NYSE: CI) concerning potential violations of federal securities laws. This follows a significant 17% drop in Cigna's stock price on October 30, 2025, after the company reported third-quarter earnings showing a higher Healthcare Medical Care Ratio (MCR) of 84.8% compared to 82.8% in the prior year, indicating reduced future profitability. The firm is inviting affected shareholders to seek additional information regarding the potential securities fraud allegations.

**4. Trump administration ups payer price transparency requirements**
- Source: TechTarget | 20251223T152105 | Somewhat-Bullish | Relevance: 77%
- The Trump administration has proposed significant updates to the Transparency in Coverage (TiC) rule, aiming to improve healthcare price transparency. These updates, developed by CMS, the Department of Labor, and the Department of the Treasury, seek to address issues like data inaccessibility and ambiguity in current compliance. The changes include reformatting data files, requiring change logs, and strengthening price comparison tools, though no new requirements for prescription drug price transparency were included.

**5. UnitedHealth Unveils 23-Point Action Plan Following Independent Business Audit**
- Source: Benzinga | 20251222T181556 | Somewhat-Bullish | Relevance: 62%
- UnitedHealth Group (NYSE:UNH) has disclosed initial findings from an independent review of its business practices and announced a 23-point action plan to address recommendations. The move comes amid increasing public scrutiny of private insurers and aims for greater transparency and operational improvement. The company expects to complete 65% of these actions by the end of 2025, with all finalized by March next year.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 8.7% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.55 indicates undervaluation relative to growth. Forward P/E 9.0x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.4B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.55 |
| Forward P/E | 9.0 |
| Current P/E | 9.3 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.6% to 0.1% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 (-0.6%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (0.89), confirming momentum. RSI neutral at 52. Volume at 59% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.13% (CS: 55) | Neutral |
| RSI_14 | 52.1 | Neutral |
| MACD Histogram | 0.89 | Bullish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 0.913x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $275.02
- **Stop Loss:** $263.62 (4.1% risk)
- **Target:** $297.82 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 105
- **Position Value:** $28,877.10
- **Portfolio %:** 28.88%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*